SOHO 2023 Scientific Program

The eleventh annual meeting of the Society of Hematologic Oncology (SOHO 2023) will be held on September 6-9, 2023 as a hybrid event (attendance in-person plus virtual access).

This 3.5-day program will focus on state-of-the-art approaches and will include a variety of educational formats including: general sessions, meet-the-professor sessions, breakfast with the expert, debates and plenary sessions.

Below you will find the SOHO 2023 Program-at-a-Glance and detailed program information listed by day. Note that SOHO members have early access to session selections. To sign-up for FREE SOHO membership, go to soho.click/join to receive a 40% discount on registration rates.

SOHO 2023 Program-at-a-Glance

Program-at-a-Glance

SOHO 2023 Detailed Program

Select a tab to view the SOHO 2023 detailed program by day.

Wednesday, September 6, 2023

Meet-the-Professor I
MTP I: AML
MTP II: ALL
MTP III: HL
MTP IV: NHL
MTP V: CML
MTP VI: MPN
MTP VII: MDS
MTP VIII: MM
MTP IX: CLL
MTP X: CT

MTP I Details
Meet-the-Professor II
MTP XI: AML
MTP XII: ALL
MTP XIII: Lymphoma 1
MTP XIV: Lymphoma 2
MTP XV: CML
MTP XVI: MPN
MTP XVII: MDS
MTP XVIII: MM
MTP XIX: CLL
MTP XX: CT

MTP II Details
7:00 AM–
7:45 AM
8:00 AM–
8:45 AM
Session I: Acute Lymphoblastic Leukemia
Chairs: Selina Luger & Elias Jabbour
  • Welcome and Opening Remarks
    Jennifer  Brown, MD, PhD  |  President, SOHO
  • Acute Leukemia of Ambiguous Lineage
    Caner Saygin, MD  |  University of Chicago, Chicago, Illinois, USA
  • Ph+ ALL – Novel Therapies
    Elias Jabbour, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Menin Inhibition for KMT2A Rearranged ALL
    Eytan  Stein, MD  |  Memorial Sloan Kettering Cancer Center, New York, New York, USA
  • Approach to Ph-Like ALL
    Ilaria Iacobucci, PhD  |  St. Jude Children's Hospital, Memphis, Tennessee, USA
  • CNS Prophylaxis in ALL
    Partow Kebriaei, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Sequencing Immunotherapies in Adults with ALL
    Bijal Shah, MD  |  H. Lee Moffitt Cancer Center, Tampa, Florida, USA
  • Role of Transplant in the Era of CAR T Cells
    Jae Park, MD  |  Memorial Sloan Kettering Cancer Center, New York, New York, USA
  • Oral Abstract  |  ALL-300
    First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia  |  Elias Jabbour, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Oral Abstract  |  ALL-363
    Comparison of Treatment Outcomes in Adolescents and Young Adults (AYA) With Philadelphia Negative Acute Lymphoblastic Leukemia (ALL) Treated With HyperCVAD and Pediatric-Inspired Protocols (PIPs)  |  Omar Shahin MBChB  |  King Hussein Cancer Center, Amman, Jordan

9:00 AM–
11:36 AM
Lunch Sessions: Independent Satellite Symposia
  • ISS Lunch Session I
    The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
    Co-Chair & Moderator | Guillermo Garcia-Manero, MD | MD Anderson Cancer Center | Houston, Texas, USA
    Co-Chair & Presenter | Amy E DeZern, MD, MHS | John Hopkins Cancer Center | Baltimore, Maryland, USA
    This live educational symposium is certified by Medical Learning Institute, Inc. for 1.0 CME/MOC/NCPD/ACPE credit/contact hour. This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education. This educational activity is supported through educational grants from Bristol Myers Squibb, Geron, and Novartis Pharmaceuticals Corporation.
    For more information and to register for this ISS, go to www.peerview.com/MDSHouston23-Live.

  • ISS Lunch Session II
    Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care
    Co-Chair & Moderator | Sagar Lonial, MD, FACP | Winship Cancer Institute, Emory University School of Medicine | Atlanta, Georgia, USA
    Co-Chair & Presenter | Krina Patel, MD, MSc | MD Anderson Cancer Center | Houston, Texas, USA
    TThis live educational symposium is certified by Medical Learning Institute, Inc. for 1.0 CME/MOC/NCPD/ACPE credit/contact hour. This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education. This activity is supported by independent medical educational grants from GSK, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and, Regeneron Pharmaceuticals, Inc.
    For more information and to register for this ISS, go to www.peerview.com/MMHouston23-Live.
11:51 AM–
12:51 PM
Plenary Session I
Chair: Sagar Lonial
  • Acute Lymphoblastic Leukemia
    Hagop Kantarjian, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
    Recipient of the Emil J Freireich Distinguished Pioneer Award
1:06 PM–
1:26 PM
Session II: Myelodysplastic Neoplasms
Chairs: Guillermo Garcia-Manero & Amy DeZern
  • Update on the Biology of MDS
    Juanjo Rodriguez Sevilla, MD, PhD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Update on Classifications and Prognostic Models
    Joseph D Khoury, MD  |  University of Nebraska, Omaha, Nebraska, USA
  • Update on CHIP and CCUS
    Lachelle D Weeks, MD, PhD  |  Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Update on Treatment of Lower Risk MDS
    Uwe Platzbecker, MD  |  Leipzig University Hospital, Leipzig, Germany
  • Update on Treatment of Higher Risk MDS
    Rami Komrokji, MD  |  H. Lee Moffitt Cancer Center, Tampa, Florida, USA
  • Oral Abstract  |  MDS-044
    Cancer Disparities in Survival of Patients With Hematologic Malignancies in the Context of Social Determinants of Health: A Systematic Review  |  Marisol Miranda-Galvis, PhD  |  Georgia Cancer Center, Augusta, Georgia, USA
  • Oral Abstract  |  MDS-157
    Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study  |  Guillermo Garcia-Manero, MD  |  MD Anderson Cancer Center, Houston, Texas, USA

1:26 PM–
3:16 PM
Session III: Acute Myeloid Leukemia
Chairs: Daniel Pollyea & Farhad Ravandi
  • What is the Future of Menin Inhibitors in AML?
    Ghayas C Issa, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Is Acute Myeloid Leukemia with Monocytic Features a Separate Entity?
    Daniel Pollyea, MD, MS  |  University of Colorado, Denver, Colorado, USA
  • What is the Role of Quizartinib in the Current Landscape of AML Therapy?
    Harry P Erba, MD, PhD  |  Duke University,  Durham, North Carolina, USA
  • Triplet Regimens in AML: Beyond Azacytidine Plus Venetoclax
    Courtney DiNardo, MD, MSCE  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Post-Transplant Maintenance Therapy
    Betul Oran, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • DEBATE: No Therapy vs Achieving Best Response Prior to Transplant
    Prior Therapy Is Not Needed for Transplanting Patients With Relapsed or Refractory AML
    Johannes Schetelig, MD  |  University of Dresden, Dresden, Germany 
    Achieving Best Response Is Desirable Prior to Allogeneic Stem Cell Transplant
    Roland Walter, MD, PhD  |  Fred Hutchinson Cancer Center, Seattle, Washington, USA
  • Familial Predisposition to AML: Prevalence and Implications for Management
    Lucy A Godley, MD, PhD  |  Northwestern University, Evanston, Illinois, USA
  • Oral Abstract  |  AML-112
    Impact of Consolidation Chemotherapy Intensity Before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia  |  Yosr Hicheri, MD  |  Institut Paoli Clamettes, Marseille, France

3:31 PM–
6:05 PM
Poster Session & Awards Reception
  • Poster Viewing & Discussion
  • Awards Ceremony
6:05 PM–
7:35 PM
Dinner Session: Independent Satellite Symposium III
  • ISS Dinner Session III
    Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations
    Co-Chair & Moderator | William G. Wierda, MD, PhD | MD Anderson Cancer Center | Houston, Texas, USA
    Co-Chair & Presenter | Nicole Lamanna, MD | Columbia University Irving Medical Center | New York, New York, USA
    Presenter | Meghan C. Thompson, MD | Memorial Sloan Kettering Cancer Center | New York, New York, USA
    This live educational symposium is certified by Medical Learning Institute, Inc. for 1.0 CME/MOC/NCPD/ACPE credit/contact hour. This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education. This activity is supported by independent educational grants from AstraZeneca; BeiGene; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.
    For more information and to register for this ISS, go to www.peerview.com/CLLHouston23-Live.
7:35 PM–
8:35 PM
8:45 PM–
9:45 PM
Dessert Session: Independent Satellite Symposia
  • ISS Dessert Session IV
    Exploring Emerging Approaches in Acute Myeloid Leukemia
    Courtney D. DiNardo, MD, MSCE | MD Anderson Cancer Center | Houston, Texas, USA
    Harry P. Erba, MD, PhD | Duke University | Durham, North Carolina, USA
    Amer Zeidan, MBBS, MHS | Yale Cancer Center | New Haven, Connecticut, USA
    This live educational symposium is certified by Medical Learning Institute, Inc. for 1.0 CME/MOC/NCPD/ACPE credit/contact hour. This activity is developed with our educational partner, Medscape Oncology for Medical Education. This activity is supported through independent medical education grants from AbbVie, Biomea, Rigel Pharmaceuticals and Syndax Pharmaceuticals.
    For more information and to register for this ISS, go to www.medscape.org/symposium/aml-novelapproaches.

Thursday, September 7, 2023

Breakfast Sessions: ISS and IES
  • ISS V Breakfast Session 
    Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms
    Co-Chair & Moderator  |  Naval Daver, MD  |  MD Anderson Cancer Center  |  Houston, Texas, USA
    Co-Chair & Presenter  | Gail J. Roboz, MD  |  Weill Medical College of Cornell University  |  New York, New York, USA
    This live educational symposium is certified by Medical Learning Institute, Inc. for 1.0 CME/MOC/NCPD/ACPE credit/contact hour. This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education. This activity is supported through educational grants from Actinium Pharmaceuticals, Astellas, and Bristol Myers Squibb.
    For more information and to register for this ISS, go to www.peerview.com/AMLHouston23-Live.




  • IES Breakfast Session (non-accredited)
    Key Considerations for Optimizing Management of Myelofibrosis Through Collaborative Care Across Practice Settings
    Bart L. Scott, MD | Fred Hutch- Seattle Cancer Care Alliance, Seattle, Washington, USA
    Frank M. Senecal, MD, FACP | Northwest Medical Specialties, Tacoma, Washington, USA
    This activity is sponsored by GlaxoSmithKline

6:45 AM–
7:45 AM
Dessert Session: Industry Expert Sessions (non-accredited)
  • IES III Dessert Session
    Treatment Options in Relapsed Refractory Multiple Myeloma: Clinical Data and Patient Cases
    Alan Rodney, MD | Texas Oncology-Deke Slayton Cancer Center | Webster, Texas, USA
    This activity is sponsored by Bristol Myers Squibb

  • IES IV Dessert Session
    An Advancement in Frontline DLBCL
    Tara Graff, DO | Mission Cancer and Blood, Des Moines, Iowa, USA
    This activity is sponsored by Genentech
Session IV: Chronic Myeloid Leukemia
Chairs: Nick Cross & Simona Soverini
  • Genomic Complexity Beyond BCR::ABL1 and Its Clinical Impact
    David Ross, MBBS, PhD, FRACP, FRCPA  |  Royal Adelaide Hospital and Institute, Adelaide, Australia
  • Epigenetic Dysregulation of CML
    Sin Tiong Ong, MD  |  Duke NUS Medical School, Singapore
  • Rational Choice of TKI
    Michael Deininger, MD, PhD  |  Versiti Blood Research Institute, Milwaukee, Wisconsin, USA
  • Cost Benefit Role of TKI Choice 
    Hagop Kantarjian, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • The New ELN Molecular Recommendations
    Nick Cross, MA, PhD, FRCPath  |  University of Southampton, Salisbury, United Kingdom
  • Oral Abstract  |  CML-310
    Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data  |  Hagop Kantarjian, MD  |  MD Anderson Cancer Center, Houston, Texas, USA


7:39 PM–
8:39 PM
8:00 AM–
9:40 AM
Session V: Myeloproliferative Neoplasms
Chairs: Francesco Passamonti & Olatoyosi Odenike
  • Modern Prognostication in Classic MPNs
    Francesco Passamonti, MD  |  University of Milan, Milan, Italy
  • Managing Accelerated & Blast Phase MPN
    Olatoyosi Odenike, MD  |  University of Chicago, Chicago, Illinois, USA
  • Choosing and Properly Using a JAK Inhibitor in Myelofibrosis
    Anthony M Hunter, MD  |  Winship Cancer Institute, Atlanta, Georgia, USA
  • Addressing Anemia in Myelofibrosis
    Stephen T Oh, MD, PhD  |  Washington University Medical School, St. Louis, Missouri, USA
  • Novel Non-JAK Inhibitor Therapies for Myelofibrosis
    John Mascarenhas, MD  |  Mount Sinai Hospital, New York, New York, USA
  • Oral Abstract  |  MPN-470
    Examining Racial Disparities in Primary Myelofibrosis Incidence and Survival Rates: A SEER Database Analysis from 2000‒2019  |  M Bakri Hammami, MD  |  Albert Einstein College of Medicine, New York, New York, USA

10:10 AM–
11:50 AM
Lunch Sessions: Independent Expert Sessions (non-accredited)
  • IES I Lunch Session
    An FDA Approved Treatment Option for Anemia in LR-MDS
    Christina Hughes | Bristol Myers Squibb | New York, New York, USA
    This activity is sponsored by Bristol Myers Squibb




  • IES II Lunch Session 
    Real-World Patient Cases in Polycythemia Vera and Myelofibrosis: A Panel Discussion on When to Intervene with Jakafi® (ruxolitinib)
    Pankit Vachhani, MD | UAB Comprehensive Cancer Center, Birmingham, Alabama, USA
    Prithviraj Bose, MD | MD Anderson Cancer Center, Houston, Texas, USA
    This activity is sponsored by Incyte
12:05 PM–
1:05 PM
Plenary Session II
Chair: Hagop Kantarjian
  • Chronic Myeloid Leukemia
    Jorge Cortés, MD  |  Augusta University, Augusta, Georgia, USA
    Recipient of the Michael J. Keating Outstanding Achievement Award
1:20 PM–
1:40 PM
Session VI: Multiple Myeloma
Chairs: Thomas Martin & Krina Patel
  • Frontline Treatment for High-Risk: Personalized?
    Saad Z Usmani, MD, MBA, FACP  |  Memorial Sloan Kettering, New York, New York, USA
  • Debate: Watch and Wait vs Treatment for Smoldering Multiple Myeloma
    Smoldering MM: Time to Watch and Wait
    Angela Dispenzieri, MD  |  Mayo Clinic Rochester, Rochester, Minnesota, USA
    Smoldering MM: Time to Treat – Personalized?
    Sagar Lonial, MD, FACP  |  Winship Cancer Institute, Atlanta, Georgia, USA
  • Treatment of Frail MM Patients—Personalized Care
    Elizabeth K. O'Donnell, MD  |  Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • BCMA/GPRC5D/FcRH5 | CARs/BsAbs—How to Choose
    Ajai Chari, MD  |  University of California, San Francisco, California, USA
  • CAR/BsAb Toxicity: Prevention, Treatment and Surveillance
    Noopur Raje, MD  |  Massachusetts General Hospital, Boston, Massachusetts, USA
  • Next Generation Therapeutics: Degraders and Targeted Therapy | Where Will They Fit? Personalized Therapy in MM
    Ajay K Nooka, MD, MPH, FACP  |  Winship Cancer Institute, Atlanta, Georgia, USA
  • Oral Abstract  |  MM-304
    Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1  |  Yi Lin, MD, PhD  |  Mayo Clinic Rochester, Rochester, Minnesota, USA
1:40 PM–
3:56 PM
Session VII: Chronic Lymphoctic Leukemia
Chairs: Susan O'Brien & Paolo Ghia
  • Clinical Significance of MBL
    Sameer A Parikh, MBBS  |  Mayo Clinic, Rochester, Minnesota, USA
  • Is FD Therapy the New SOC in FL CLL?
    Alessandra Ferrajoli, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Debate: Stop vs Continue VenG: MRD+ at 1 Year of VenG
    MRD+ at 1 Year of VenG: Stop Therapy
    Othman Al-Sawaf, MD  |  University Hospital of Cologne, Cologne, Germany
    MRD+ at 1 Year of VenG: Continue VenG
    Nicole Lamanna, MD  |  Herbert Irving Comprehensive Cancer Center, New York, New York, USA
  • How We Developed a Curative Therapy for CLL and Stopped Using It
    John Seymour, MBBS, FRACP, PhD  |  Peter MacCallum Cancer Centre, Melbourne, Australia
  • How Biologic Markers Impact Outcomes With Novel Therapy
    Talha Munir, MD  |  St. James’s Hospital, Leeds, United Kingdom
  • Oral Abstract  |  CLL-094
    Lisocabtagene Maraleucel (liso-cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study  |  Tanya Siddiqi MD  |  City of Hope Cancer Center, Duarte, California, USA
4:26 PM–
6:24 PM
Dinner Session: Independent Satellite Symposia
  • ISS Dinner Session VI
    Relapsed, Intolerant or Refractory? Treatment Selection and Sequencing Across the Multiple Myeloma Continuum
    Marc J. Braunstein, MD   |   NYU Long Island School of Medicine   |   New York, New York, USA
    Krina K. Patel, MD, MSc   |   The University of Texas MD Anderson Cancer Center   |   Houston, Texas, USA
    Raphael Szalat, MD   |   Boston University School of Medicine   |   Boston, Massachusetts, USA
    This live educational symposium is certified by Medical Learning Institute, Inc. for 1.0 CME/MOC/NCPD/ACPE credit/contact hour. This activity is developed with our educational partner, Haymarket Medical Education for Medical Education. This activity is supported through independent medical education grants from Bristol Myers Squibb and Sanofi.
    For more information and to register for this ISS, go to myCME.com/RRMMLive2023.

  • ISS Dinner Session VII
    Consensus or Controversy? Documenting and Discussing Clinical Investigators’ Practice Patterns in Myelofibrosis
    Moderator | John Mascarenhas, MD | Icahn School of Medicine at Mount Sinai | New York, New York, USA
    Faculty | Prithviraj Bose, MD | MD Anderson Cancer Center | Houston, Texas, USA
    Faculty | Andrew T Kuykendall, MD | Moffitt Cancer Center, University of South Florida | Tampa, Florida, USA
    This live educational symposium is certified by Medical Learning Institute, Inc. for 1.0 CME credit/contact hour. This activity is developed with our educational partner, Research To Practice for Medical Education. This activity is supported through independent medical education grants from Bristol Myers Squibb, CTI Biopharma Corp, and GlaxoSmithKline.
    For more information and to register for this ISS, go to http://www.researchtopractice.com/Meetings/SOHO2023.
6:34 PM–
7:34 PM

Friday, September 8, 2023

Breakfast Sessions: ISS and Expert Breakfast
  • ISS VIII Breakfast Session 
    Mantle Cell Lymphoma: Novel Therapeutic Strategies Using the New Generation of BTK Inhibitors
    Program Director | Julie Vose, MD, MBA | University of Nebraska Medical Center | Omaha, Nebraska, USA
    Faculty | Brad Kahl, MD | Professor of Medicine and Director of the Lymphoma Program | Washington University School of Medicine | St Louis, MO, USA
    This live educational symposium is certified by Medical Learning Institute, Inc. for 1.0 CME/MOC/NCPD/ACPE credit/contact hour. This activity is developed with our educational partner, Clinical Care Options, LLC. for Medical Education. This activity is supported through independent medical education grants from AstraZeneca, Lilly, and Merck Sharp & Dohme Corp.
    For more information and to register for this ISS, go to https://www.clinicaloptions.com/MCLBTKiHouston2023.

  • Breakfast with the Expert II
    CML and Pregnancy
    Elisabetta Abruzzese, MD, PhD  |  S. Eugenio University Hospital, Rome, Italy
6:45 AM–
7:45 AM
Dinner Session: Industry Expert Sessions (non-accredited)
  • IES Dinner  Session VII
    A First-in-Class NME in 3L+ Follicular Lymphoma
    Sujith Kalmadi , MD | Ironwood Cancer Center, Chandler, Arizona, USA
    This activity is sponsored by Genentech

  • IES Dinner Session VIII
    Exploring Time off Treatment with a BCL-2 Inhibitor
    Cyrus Khan, MD | Allegheny Health Network Cancer Institute
    This activity is sponsored by Genentech
Session VIII: T-Cell Lymphoma
Chairs: Barbara Pro & Jasmine Zain
  • New Insights Into the Pathogenesis of T-Cell Lymphoma and How This May Guide Treatment
    Laurence de Leval, MD, PhD  |  University Hospital of Lausanne, Lausanne, Switzerland
  • Tailoring Therapy In PTCL
    Jasmine M Zain, MD  |  City of Hope Cancer Center, Duarte, California, USA
  • Managing Rare T-Cell Lymphoma Subtypes
    Barbara Pro, MD  |  Columbia University, New York, New York, USA
  • Novel Targeted Agents in T-Cell Lymphoma
    Pier Luigi Zinzani, MD, PhD  |  University of Bologna, Bologna, Italy
  • A Multidisciplinary Approach to the Management of Mycosis Fungoides
    Christiane Querfeld, MD, PhD  |  City of Hope Cancer Center, Duarte, California, USA


6:53 PM–
7:53 PM
8:00 AM–
9:30 AM
Session IX: Indolent B-Cell Lymphoma
Chairs: Brad Kahl & Emanuele Zucca
  • Treatment of Follicular Lymphoma, What is the New Order?
    Brad S Kahl, MD  |  Washington University Medical School, St. Louis, Missouri, USA
  • Bispecific Antibodies or CAR T-Cells for Indolent NHL?
    Caron A Jacobson, MD, MMSc  |  Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Novel Combinations in Indolent Lymphoma
    Paolo Strati, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Treatment Options for Marginal Zone Lymphoma
    Emanuele Zucca, MD  |  Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
  • Oral Abstract  |  IBCL-098
    TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)  |  Loretta J. Nastoupil, MD  |  MD Anderson Cancer Center, Houston, Texas, USA



10:00 AM–
11:22 AM
Lunch Sessions: Independent Satellite Symposia
  • ISS IX Lunch Session 
    Pacing the Continuum of Follicular Lymphoma: Integrating Prognostic Tools and Novel Treatment Approaches
    Tycel Phillips, MD | City of Hope | Duarte, California, USA
    Krish Patel, MD | Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute | Seattle, Washington, USA
    Adrienne A. Phillips, MD, MPH | RWJ Barnabas Health and Rutgers Cancer Institute | New Brunswick, NJ, USA
    This live educational symposium is certified by Medical Learning Institute, Inc. for 1.0 CME/MOC/NCPD/ACPE credit/contact hour. This activity is supported through independent medical education grant from Regeneron Pharmaceuticals Inc.
    For more information and to register for this ISS, go to https://mli.link/soho2023-FL.







  • ISS X Lunch Session 
    Cases From The Community: Investigators Discuss the Application of Available Research in the Care of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
    Moderator | Christopher R Flowers, MD, MS | MD Anderson Cancer Center | Houston, Texas, USA
    Matthew Lunning, DO | Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center | Omaha, Nebraska, USA
    Faculty | Laurie H Sehn, MD, MPH | BC Cancer Centre for Lymphoid Cancer, University of British Columbia | Vancouver, British Columbia, Canada
    This live educational symposium is certified by Medical Learning Institute, Inc. for 1.0 CME credit/contact hour. This activity is developed with our educational partner, Research To Practice for Medical Education. This activity is supported through independent medical education grants from ADC Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc. and AbbVie Inc., and Regeneron Pharmaceuticals Inc.
    For more information and to register for this ISS, go to http://www.researchtopractice.com/Meetings/SOHO2023.
11:37 AM–
12:37 PM
Plenary Session III
Chair: Susan O'Brien
  • Emerging BCL 2 Inhibitors
    Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD   |  Royal Melbourne Hospital, Melbourne, Australia
12:52 PM–
1:12 PM
Session X: Aggressive B-Cell Lymphoma
Chairs: Laurie Sehn & Christopher Flowers
  • Incorporating Novel Agents in Frontline DLBCL
    Laurie Sehn, MD, MPH  |  BC Cancer Agency, Vancouver, Canada
  • The New Algorithm for Second-Line LBCL
    Jason Westin, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • The Emergence of Bispecific Antibodies in Aggressive B-Cell Lymphoma
    Martin Hutchings, MD, PhD  |  Copenhagen University Hospital, Copenhagen, Denmark
  • Optimizing the Use of Novel Agents in Relapsed/Refractory DLBCL
    Christopher Flowers, MD, MS  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Treatment Options for Primary Mediastinal B-Cell Lymphoma
    Kieron Dunleavy, MD  |  Georgetown University, Washington, DC, USA
  • The Treatment of Primary and Secondary CNS Lymphoma
    Kate Cwynarski, MBBS, PhD, FRCP, FRCPath  |  University College London, London, United Kingdom
  • Oral Abstract  |  ABCL-500
    Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial  |  Yasmin Karimi, MD  |  University of Michigan, Ann Arbor, Michigan, USA  |  University of Michigan, Ann Arbor, Michigan, USA
1:12 PM–
3:10 PM
Session XI: Mantle Cell Lymphoma
Chairs: Anita Kumar & Tycel Phillips
  • Is Stem Cell Transplantation Still Necessary in Frontline Mantle Cell Lymphoma?
    Timothy Fenske, MD, MS  |  Froedtert Hospital, Milwaukee, Wisconsin, USA
  • What is High Risk Mantle Cell Lymphoma and How Should We Treat It?
    Anita Kumar, MD   |  Memorial Sloan Kettering, New York, New York, USA
  • CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma
    Tycel J Phillips, MD  |  City of Hope Cancer Center, Duarte, California, USA
  • Emerging Novel Agents in Mantle Cell Lymphoma
    Kami J Maddocks, MD  |  Ohio State University, Columbus, Ohio, USA
3:40 PM–
4:52 PM
Session XII: Hodgkin Lymphoma
Chairs: Catherine Diefenbach & Jonathan Friedberg
  • Risk-Based Treatment of Hodgkin Lymphoma in the Era of Novel Therapies
    Catherine S Diefenbach, MD  |  NYU Langone Health, New York, New York, USA
  • Treatment of HL in Older Patients
    Jonathan W Friedberg, MD, MMSc  |  University of Rochester Medical Center, Rochester, USA
  • Oral Abstract  |  HL-642
    Does Interim PET Assessment After Two Cycles of Treatment With Brentuximab Vedotin Still Have a Predictive Value in Hodgkin Lymphoma?  |  Ravand Samaeekia, MD, MS  |  Loma Linda University Cancer Center, Loma Linda, California, USA



4:52 PM–
5:38 PM
Hors d'Oeuvres and Cocktails: Industry Expert Sessions (non-accredited)
  • IES Hors d'Oeuvres Session V
    A Treatment Option for Relapsed or Refractory Multiple Myeloma
    Siddhartha Ganguly, MD | Houston Methodist Hospital, Houston, TX
    This activity is sponsored by Pfizer
  • IES Hors d'Oeuvres Session VI
    CALQUENCE- A BTKI for the Treatment of CLL/SLL With Updated Clinical Trial Data and Tablet Formulation
    John Renshaw, MD | Texas Oncology | San Antonio, Texas, USA| Texas Oncology, P.A.
    This activity is sponsored by AstraZeneca
5:48 PM–
6:48 PM
5:48 PM–
6:48 PM
Dessert Session: Industry Expert Session (non-accredited)
  • IES Dessert Session IX
    CAR T-Cell Therapy For the Treatment of B-Cell Lymphomas
    TBA
    This activity is sponsored by Gilead
7:58 PM–
8:58 PM

Saturday, September 9, 2023

Breakfast Sessions: ISS and Expert Breakfast
  • ISS XI Breakfast Session 
    Integration of CAR T-cell Therapy Across B-Cell Lymphomas in Community-Based Practices
    Loretta J. Nastoupil, MD | Associate Professor Director | MD Anderson Cancer Center | Houston, TX, USA
    Sunil Patel, MD, CMQ, MBA | Kelsey-Seybold Clinic | Houston, TX, USA
    Tanya Siddiqi, MD | City of Hope Cancer Center | Duarte, CA, USA
    This live educational symposium is certified by Medical Learning Institute, Inc. for 1.0 CME/MOC/NCPD/ACPE credit/contact hour. This activity is developed with our educational partner, Haymarket Medical Education for Medical Education. This activity is supported through independent medical education grant from Bristol Myers Squibb. For more information and to register for this ISS, go to myCME.com/CARTLive2023.

  • Breakfast with the Expert III
    Harnessing the Immune System in Patients With Lymphoma
    Stephen M Ansell, MD, PhD  |  Mayo Clinic Rochester, Rochester, Minnesota, USA
6:45 AM–
7:45 AM
Session XIII: Cellular Therapy
Chairs: Krina Patel & Hugo Fernandez
  • DEBATE: Early vs Delayed HCT in Myeloma
    Early HCT in Myeloma
    Natalie S Callander, MD  |  University of Wisconsin, Madison, Wisconsin, USA
    Late HCT in Myeloma
    Clifton C Mo, MD  |  Dana-Farber Cancer Institute, Boston, Massachusetts, USA

  • DEBATE: Should Patients with AML and Active Disease be Transplanted?
    PRO 
    Boglarka Gyurkocza, MD   |  Memorial Sloan Kettering, New York, New York, USA
    CON
    Edmund K Waller, MD, PhD, FACP  |  Winship Cancer Institute, Atlanta, Georgia, USA

  • Oral Abstract  |  CT-186
    Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia (AML) with FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial  |  Alexander Perl, MD, MS  |  University of Pennsylvania, Philadelphia, Pennsylvania, USA
8:00 AM–
9:22 AM
Session XIV: Next Questions
Chairs: Jennifer Brown & Guillermo Garcia-Manero
  • Next Questions: Myeloproliferative Neoplasms
    John Mascarenhas, MD  |  Mount Sinai Hospital, New York, New York, USA
  • Next Questions: Acute Myeloid Leukemia
    Farhad Ravandi, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Next Questions: Cellular Therapy
    Marcos de Lima, MD  |  Ohio State University, Columbus, Ohio, USA
  • Next Questions: Chronic Lymphocytic Leukemia
    Nitin Jain, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Next Questions: Chronic Myeloid Leukemia
    Philippe Rousselot, MD, PhD  |  Mignot University de Versailles, Saint-Quentin-en-Yvelines, Paris, France
  • Next Questions: Aggressive B-Cell Lymphoma
    Grzegorz S Nowakowski, MD   |  Mayo Clinic Rochester, Rochester, Minnesota, USA
  • Next Questions: Indolent B-Cell Lymphoma
    Loretta Nastoupil, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Next Questions: T-Cell Lymphoma
    Matthew A Lunning, DO  |  University of Nebraska, Omaha, Nebraska, USA
  • Next Questions: Mantle Cell Lymphoma
    Andre Goy, MD, MS  |  Hackensack University, Hackensack, New Jersey, USA
  • Next Questions: Hodgkin Lymphoma
    Alex Herrera, MD  |  City of Hope Cancer Center, Duarte, California, USA
  • Next Questions: Multiple Myeloma
    Robert Z Orlowski, MD, PhD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Next Questions: Myelodysplastic Neoplasms
    Guillermo Garcia-Manero, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Next Questions: Acute Lymphoblastic Leukemia
    Elias Jabbour, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
9:52 AM–
12:02 PM
SOHO 2023: Closing Session
  • Closing Remarks
    Jennifer R Brown, MD, PhD  |  President, Society of Hematologic Oncology
    and, Director, Chronic Lymphocytic Leukemia (CLL) Center Institute Physician Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology, Harvard Medical School
  • SOHO 2023 Drawing
  • Adjourn
12:02 PM–
12:17 PM